Clinical Trial

Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia

Study acronym: TOCIVENA
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1, open label, interventional, single center, in patients with Acute Myeloid Leukemia (AML). This study will investigate dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy. The patient population will consist of adults men and women at least 18 years, who meet eligibility criteria. In this study propose combining tocilizumab with the standard treatment of azacitidine and venetoclax for patients with AML who are not eligible for intensive treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-30.
Trial Details
NCT Number NCT07392814
Lead Sponsor Nantes University Hospital
Conditions Leukemia Acute Myeloid - AML
Enrollment 12 participants
Start Date 2026-03-10
Primary Completion 2028-07-10 (estimated)
Study Completion 2030-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-17